Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate -

Advanced Cancer Therapeutics (ACT), a private company dedicated to bringing new anti-cancer therapies market, announced today (4 June) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidates that inactivates a new cancer metabolism target never examined in human clinical trials. The Food and Drug Administration of the United States approved Phase 1 dose escalation study is to evaluate the safety activity, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer.

PFK-158 is the first-6-phosphofructo-2-kinase / fructose-2,6-bisphosphatase 3 (PFKFB3) inhibitor undergoing clinical trial test in cancer patients. The target, PFKFB3 is activated oncogenes and the lean state oxygen in cancers, stimulates glucose metabolism and is required for the growth of cancer cells in mice form tumors. PFK-158, which was authorized by ACT Cancer Center James Graham Brown at the University of Louisville, inhibits the field of PFKFB3 link causing a marked reduction in glucose uptake and growth of several types of cancer in mouse substrate.

PFK-158 human clinical trials have begun recruiting patients in May with the first clinical trial site in the James Graham Brown Cancer Center, part of KentuckyOne Health. In the weeks following the opening of the first clinical trial site, ACT was able to open the second trial site at the Medical Center of Georgetown University in Washington, also in May.

According to Jason A. Chesney, MD, Ph.D., Assistant director of the Brown Cancer Center and leader of world thought and researcher in cancer metabolism, "PFK-158 is not only a first in class drug against cancer, but also the first to target glucose metabolism by inhibiting PFKFB3. This unique mechanism of action led to the effectiveness against a broad range of human cancers caused by mutations common and synergy with targeted agents that are FDA approved for several types of cancer.

"as a researcher, it's incredibly rewarding to assist your group studies move into clinical trials and potentially save life of cancer patients, "said Chesney.

"This is an important milestone for ACT and supports our commitment to develop advanced important treatment for cancer patients with first in class potential revolutionary therapeutic as PFK-158," said Randall B. Riggs, president and CEO of ACT.